Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated:  9/27/2017
Medical University of South Carolina
mi
from
Charleston, SC
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated: 9/27/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated:  9/27/2017
Baylor University Medical Center
mi
from
Dallas, TX
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated: 9/27/2017
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated:  9/27/2017
University of Texas MD Anderson Cancer Research Center
mi
from
Houston, TX
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated: 9/27/2017
University of Texas MD Anderson Cancer Research Center
mi
from
Houston, TX
Click here to add this to my saved trials
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated:  9/27/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated: 9/27/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated:  9/27/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated: 9/27/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated:  9/27/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated: 9/27/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated:  9/27/2017
Levine Children's Hospital at Carolinas Medical Center
mi
from
Charlotte, NC
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)
Status: Enrolling
Updated: 9/27/2017
Levine Children's Hospital at Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
University of Alabama
mi
from
Birmingham, AL
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Community Medical Research
mi
from
Miami, FL
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Community Medical Research
mi
from
Miami, FL
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Community Medical Research - North Miami
mi
from
North Miami, FL
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Community Medical Research - North Miami
mi
from
North Miami, FL
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Massachusetts General
mi
from
Boston, MA
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Massachusetts General
mi
from
Boston, MA
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Brigham and Women's Hosp
mi
from
Boston, MA
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
St. Vincent Hospital
mi
from
Worcester, MA
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
St. Vincent Hospital
mi
from
Worcester, MA
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
New York Methodist Hospital
mi
from
Brooklyn, NY
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
New York Methodist Hospital
mi
from
Brooklyn, NY
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Clinical Research Associates
mi
from
Nashville, TN
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Clinical Research Associates
mi
from
Nashville, TN
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Vanderbilt University School of Medicine
mi
from
Nashville, TN
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Vanderbilt University School of Medicine
mi
from
Nashville, TN
Click here to add this to my saved trials
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated:  9/30/2017
Benchmark Research
mi
from
San Angelo, TX
FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection
Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection
Status: Enrolling
Updated: 9/30/2017
Benchmark Research
mi
from
San Angelo, TX
Click here to add this to my saved trials
Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution
Phase 1/2 Study to Evaluate the Safety and Effectiveness of Novel Non-Antibiotic, Non-Heparin Nitroglycerin Based Catheter Lock Solution Used for the Prevention of Intraluminal Central Venous Catheter (CVC) Infections in Cancer Patients
Status: Enrolling
Updated:  10/2/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution
Phase 1/2 Study to Evaluate the Safety and Effectiveness of Novel Non-Antibiotic, Non-Heparin Nitroglycerin Based Catheter Lock Solution Used for the Prevention of Intraluminal Central Venous Catheter (CVC) Infections in Cancer Patients
Status: Enrolling
Updated: 10/2/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated:  10/3/2017
Laguna Hills
mi
from
Laguna Hills, CA
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated: 10/3/2017
Laguna Hills
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated:  10/3/2017
Ventura
mi
from
Ventura, CA
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated: 10/3/2017
Ventura
mi
from
Ventura, CA
Click here to add this to my saved trials
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated:  10/3/2017
Butte
mi
from
Butte, MT
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated: 10/3/2017
Butte
mi
from
Butte, MT
Click here to add this to my saved trials
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated:  10/3/2017
Liberec
mi
from
Liberec,
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated: 10/3/2017
Liberec
mi
from
Liberec,
Click here to add this to my saved trials
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated:  10/3/2017
Idaho
mi
from
Idaho Falls, ID
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated: 10/3/2017
Idaho
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated:  10/3/2017
New Jersey
mi
from
Somers Point, NJ
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)
Status: Enrolling
Updated: 10/3/2017
New Jersey
mi
from
Somers Point, NJ
Click here to add this to my saved trials
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated:  10/4/2017
Arkansas Children's Hospital
mi
from
Little Rock, AR
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated: 10/4/2017
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated:  10/4/2017
University of Louisiana at Monroe
mi
from
Shreveport, LA
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated: 10/4/2017
University of Louisiana at Monroe
mi
from
Shreveport, LA
Click here to add this to my saved trials
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated:  10/4/2017
Toledo Children's Hospital
mi
from
Toledo, OH
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated: 10/4/2017
Toledo Children's Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated:  10/4/2017
Children's Hospital of Orange County
mi
from
Orange, CA
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated: 10/4/2017
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated:  10/4/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated: 10/4/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated:  10/4/2017
Children's Mercy Hospital and Clinics
mi
from
Kansas City, MO
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated: 10/4/2017
Children's Mercy Hospital and Clinics
mi
from
Kansas City, MO
Click here to add this to my saved trials
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated:  10/4/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated: 10/4/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated:  10/4/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics
Status: Enrolling
Updated: 10/4/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study
Acupuncture Augmentation of Lidocaine for the Treatment of Provoked, Localized vulvodynia-a Feasibility and Acceptability Pilot Study
Status: Enrolling
Updated:  10/4/2017
Women's Health Research Unit; Oregon Health & Science University
mi
from
Portland, OR
Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study
Acupuncture Augmentation of Lidocaine for the Treatment of Provoked, Localized vulvodynia-a Feasibility and Acceptability Pilot Study
Status: Enrolling
Updated: 10/4/2017
Women's Health Research Unit; Oregon Health & Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated:  10/5/2017
Family and Medical Counseling Service
mi
from
Washington, D.C.,
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated: 10/5/2017
Family and Medical Counseling Service
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated:  10/5/2017
Unity Health Care/Walker Jones
mi
from
Washington, D.C.,
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated: 10/5/2017
Unity Health Care/Walker Jones
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated:  10/5/2017
Whitman Walker Clinic
mi
from
Washington, D.C.,
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated: 10/5/2017
Whitman Walker Clinic
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Leukapheresis for Research on HCV-Coinfected Patients
Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Quantifying and Understanding the Signs and Symptoms of Fever
Beyond Intuition: Quantifying and Understanding the Signs and Symptoms of Fever
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Quantifying and Understanding the Signs and Symptoms of Fever
Beyond Intuition: Quantifying and Understanding the Signs and Symptoms of Fever
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory
Status: Enrolling
Updated:  10/5/2017
Rocky Mountain Laboratory (RML)
mi
from
Hamilton, MT
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory
Status: Enrolling
Updated: 10/5/2017
Rocky Mountain Laboratory (RML)
mi
from
Hamilton, MT
Click here to add this to my saved trials
Rituximab for Autoimmune Retinopathy
Rituximab for Autoimmune Retinopathy
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Rituximab for Autoimmune Retinopathy
Rituximab for Autoimmune Retinopathy
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance
A Phase 2b, Multicenter, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Short-Course Antimicrobial Therapy for Young Children With Acute Otitis Media (AOM) and Impact on Antimicrobial Resistance
Status: Enrolling
Updated:  10/5/2017
Kentucky Pediatric/ Adult Research
mi
from
Bardstown, KY
Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance
A Phase 2b, Multicenter, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Short-Course Antimicrobial Therapy for Young Children With Acute Otitis Media (AOM) and Impact on Antimicrobial Resistance
Status: Enrolling
Updated: 10/5/2017
Kentucky Pediatric/ Adult Research
mi
from
Bardstown, KY
Click here to add this to my saved trials
Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance
A Phase 2b, Multicenter, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Short-Course Antimicrobial Therapy for Young Children With Acute Otitis Media (AOM) and Impact on Antimicrobial Resistance
Status: Enrolling
Updated:  10/5/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance
A Phase 2b, Multicenter, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Short-Course Antimicrobial Therapy for Young Children With Acute Otitis Media (AOM) and Impact on Antimicrobial Resistance
Status: Enrolling
Updated: 10/5/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Topical Nasal Poly-ICLC
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Topical Nasal Poly-ICLC
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Status: Enrolling
Updated:  10/6/2017
Center for Clinical Studies
mi
from
Houston, TX
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Status: Enrolling
Updated: 10/6/2017
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Status: Enrolling
Updated:  10/6/2017
Center for Clinical Studies - Clear Lake/Webster
mi
from
Webster, TX
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Status: Enrolling
Updated: 10/6/2017
Center for Clinical Studies - Clear Lake/Webster
mi
from
Webster, TX
Click here to add this to my saved trials
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Status: Enrolling
Updated:  10/6/2017
Center for Clinical Studies - Houston
mi
from
Houston, TX
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Status: Enrolling
Updated: 10/6/2017
Center for Clinical Studies - Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Status: Enrolling
Updated:  10/6/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Status: Enrolling
Updated: 10/6/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Status: Enrolling
Updated:  10/6/2017
Indiana University Infectious Disease Research
mi
from
Indianapolis, IN
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Status: Enrolling
Updated: 10/6/2017
Indiana University Infectious Disease Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials